BR112015022469A2 - peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu - Google Patents

peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu

Info

Publication number
BR112015022469A2
BR112015022469A2 BR112015022469A BR112015022469A BR112015022469A2 BR 112015022469 A2 BR112015022469 A2 BR 112015022469A2 BR 112015022469 A BR112015022469 A BR 112015022469A BR 112015022469 A BR112015022469 A BR 112015022469A BR 112015022469 A2 BR112015022469 A2 BR 112015022469A2
Authority
BR
Brazil
Prior art keywords
peptide
analog
promoting
regeneration
composition
Prior art date
Application number
BR112015022469A
Other languages
English (en)
Inventor
Liu Liping
Bai Ru
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of BR112015022469A2 publication Critical patent/BR112015022469A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu a invenção proporciona peptídeos e análogos de peptídeos ingap e hip. os peptídeos e análogos podem ser usados em métodos para o tratamento de várias doenças e condições. tais doenças e condições podem incluir função pancreática debilitada, tratamento de uma doença metabólica, por exemplo, diabetes, ambas as diabetes de tipo 1 e tipo 2, indução, expansão e proliferação de ilhotas para transplante, promoção de neuroproteção ou regeneração de nervos, promoção da regeneração do fígado ou inibição de inflamação. 1/1
BR112015022469A 2013-03-15 2014-03-14 peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu BR112015022469A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072771 WO2014139182A1 (en) 2013-03-15 2013-03-15 Compositions and methods of using islet neogenesis peptides and analogs thereof
PCT/CN2014/073483 WO2014139472A1 (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Publications (1)

Publication Number Publication Date
BR112015022469A2 true BR112015022469A2 (pt) 2017-07-18

Family

ID=51535856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022469A BR112015022469A2 (pt) 2013-03-15 2014-03-14 peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu

Country Status (14)

Country Link
US (7) US20160039877A1 (pt)
EP (2) EP2970385B1 (pt)
JP (2) JP6674258B2 (pt)
KR (1) KR102244349B1 (pt)
AU (3) AU2014231444B2 (pt)
BR (1) BR112015022469A2 (pt)
CA (1) CA2906240C (pt)
ES (1) ES2703110T3 (pt)
IL (1) IL241383B (pt)
MX (2) MX2015012038A (pt)
NZ (1) NZ711958A (pt)
RU (1) RU2685958C2 (pt)
SG (1) SG11201507404RA (pt)
WO (2) WO2014139182A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560952B2 (ja) * 1999-12-03 2010-10-13 株式会社セガ ゲーム装置及びゲームシステム
CA2901404A1 (en) * 2013-02-15 2014-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes
US10137088B2 (en) 2016-02-10 2018-11-27 Pfizer Inc. Therapeutic nanoparticles having EGFR ligands and methods of making and using same
CN108616978B (zh) * 2016-12-14 2022-04-15 中兴通讯股份有限公司 一种网络功能实体进行无状态处理的方法及装置
KR102006890B1 (ko) * 2016-12-27 2019-08-05 한양대학교 산학협력단 췌장 소도 세포 표적 펩타이드 및 이의 용도
BR112019023511A2 (pt) * 2017-05-11 2020-05-19 Shenzhen Hightide Biopharmaceutical Ltd uso de compostos peptídeos no tratamento de pancreatite aguda
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
CN114644683B (zh) * 2018-09-18 2023-09-12 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
JP2023524061A (ja) * 2020-05-01 2023-06-08 ザ・ブロード・インスティテュート・インコーポレイテッド 操作された中枢神経系用組成物
WO2023143446A1 (en) * 2022-01-25 2023-08-03 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating cytokine storm

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5804421A (en) 1996-10-30 1998-09-08 Eastern Virginia Medical School Of The Medical College Fo Hampton Roads High level of expression of ingap in bacterial and euraryotic cells
US5935813A (en) 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040018623A1 (en) 1999-10-29 2004-01-29 Lawrence Rosenberg Medium for preparing dedifferentiated cells
US20020009730A1 (en) 1999-11-17 2002-01-24 Alex Chenchik Human stress array
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE10056802B4 (de) 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
ATE431851T1 (de) 2000-12-13 2009-06-15 Anaphore Inc Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c- typ lectin-ähnlichen domäne als gerüststruktur
AU2002246808A1 (en) 2000-12-19 2002-08-06 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
US20040018970A1 (en) 2000-12-19 2004-01-29 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
US6986994B2 (en) 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays
WO2002070551A2 (en) 2001-03-01 2002-09-12 Mcgill University Neuritogenic compound and uses thereof
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7662768B2 (en) 2002-01-11 2010-02-16 Mcgill University Transdifferentiation of pancreatic acinar cells
US7166439B2 (en) 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
AU2003241388A1 (en) 2002-05-09 2003-11-11 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
US20060105333A1 (en) 2002-07-10 2006-05-18 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
JP2004065120A (ja) 2002-08-07 2004-03-04 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患の疾患マーカー及びその利用
ATE452650T1 (de) 2002-08-30 2010-01-15 Biorexis Pharmaceutical Corp Transferrin-fusionsproteinbibliotheken
US20060009516A1 (en) 2002-10-24 2006-01-12 Mcgill University Use of ingap for reversing diabetes
AU2003294828A1 (en) 2002-12-17 2004-07-09 Sinogenomax Co. Ltd. Chinese National Human Genomecenter Specific markers for pancreatic cancer
US7510708B2 (en) 2003-04-14 2009-03-31 Washington University Disruption of the REG pathway
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
CN1964987A (zh) 2004-06-04 2007-05-16 惠氏公司 Regⅲ蛋白的抑制剂作为哮喘的治疗剂
KR100639677B1 (ko) 2004-11-08 2006-10-30 삼성전자주식회사 위상 및 지연 동기 루프와 이를 구비한 반도체 메모리 장치
KR100664586B1 (ko) 2004-12-22 2007-01-04 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7393919B2 (en) * 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
PL3524261T3 (pl) 2005-08-19 2024-04-15 Amylin Pharmaceuticals, Llc Eksendyna do stosowania w leczeniu cukrzycy i zmniejszania masy ciała
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US20080039393A1 (en) 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
CA2629113A1 (en) 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
WO2007071437A2 (en) 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
US20090269313A1 (en) 2006-07-19 2009-10-29 Diakine Therapeutics, Inc. Encapsulation system
KR20060089873A (ko) 2006-07-25 2006-08-09 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008085601A2 (en) 2006-11-02 2008-07-17 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
FR2910311B1 (fr) 2006-12-20 2009-02-13 Oreal Composition comprenant un compose silicone et un organosilane particulier
US7923014B2 (en) 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
WO2008118948A1 (en) * 2007-03-26 2008-10-02 Atherogenics, Inc. Methods and compositions of derivatives of probucol for the treatment of diabetes
US20080280985A1 (en) 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US8816047B2 (en) * 2007-08-30 2014-08-26 Cure DM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
SG185972A1 (en) 2007-11-07 2012-12-28 Genentech Inc Compositions and methods for treatment of microbial disorders
MX2010005893A (es) 2007-11-29 2011-03-04 Genentech Inc Star Marcadores de expresion genica para enfermedad inflamatoria de intestino.
US20100004213A1 (en) 2007-11-29 2010-01-07 Abbas Alexander R Gene expression markers for inflammatory bowel disease
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2009097155A1 (en) 2008-01-31 2009-08-06 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP2010085375A (ja) 2008-10-02 2010-04-15 Nationa Hospital Organization 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8012928B2 (en) 2008-12-19 2011-09-06 The Research Foundation Of State University Of New York Truncated PAP2 and methods of making and using same
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
ES2356217B1 (es) 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
EP2486132A1 (en) 2009-10-09 2012-08-15 Anaphore, Inc. Combinatorial libraries based on c-type lectin domain
CA2777162A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
ES2374370B1 (es) 2010-08-04 2013-01-08 Universidad De Salamanca Método para la detección de daño renal.
CN102827253B (zh) * 2011-06-17 2017-07-21 上海市第一人民医院 一种抑制炎症反应的小分子多肽及其应用
CA2901404A1 (en) * 2013-02-15 2014-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes

Also Published As

Publication number Publication date
JP2016512205A (ja) 2016-04-25
AU2020280993B2 (en) 2022-04-21
EP3473642A2 (en) 2019-04-24
IL241383B (en) 2021-03-25
RU2015143655A (ru) 2017-04-26
CA2906240A1 (en) 2014-09-18
EP2970385B1 (en) 2018-10-03
RU2015143655A3 (pt) 2018-02-28
AU2020280993A1 (en) 2021-01-07
JP2020062028A (ja) 2020-04-23
EP2970385A1 (en) 2016-01-20
US20220348618A1 (en) 2022-11-03
RU2685958C2 (ru) 2019-04-23
AU2018241212A1 (en) 2018-11-29
US20170002049A1 (en) 2017-01-05
EP3473642A3 (en) 2019-07-10
US10899815B2 (en) 2021-01-26
CA2906240C (en) 2022-10-18
WO2014139182A1 (en) 2014-09-18
WO2014139472A1 (en) 2014-09-18
US9388215B2 (en) 2016-07-12
SG11201507404RA (en) 2015-10-29
EP3473642B1 (en) 2022-04-13
US20180009861A1 (en) 2018-01-11
NZ711958A (en) 2020-07-31
JP7075918B2 (ja) 2022-05-26
EP2970385A4 (en) 2016-12-07
JP6674258B2 (ja) 2020-04-01
AU2014231444A1 (en) 2015-10-01
ES2703110T3 (es) 2019-03-07
KR20160012992A (ko) 2016-02-03
MX2015012038A (es) 2016-06-02
US20190023755A1 (en) 2019-01-24
AU2014231444B2 (en) 2018-07-19
US20150203538A1 (en) 2015-07-23
IL241383A0 (en) 2015-11-30
US9738695B2 (en) 2017-08-22
US20160039877A1 (en) 2016-02-11
MX2019009886A (es) 2019-10-22
AU2018241212B2 (en) 2020-09-17
KR102244349B1 (ko) 2021-04-23
US20200347106A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
Fan et al. Naringin promotes differentiation of bone marrow stem cells into osteoblasts by upregulating the expression levels of microRNA‑20a and downregulating the expression levels of PPARγ
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
BR112014006684A2 (pt) análogos de glucagon
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
PE20170950A1 (es) Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
BR112016008540A2 (pt) análogos de glucagon
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
BR112020026125A8 (pt) Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
BR112015022507A2 (pt) ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BR112019004534A2 (pt) análogo de amilina, método para a síntese e composição farmacêutica
BR112012013868A8 (pt) composição, proteína de fusão, polinucleotídeo, vetor ou constructo de gene, célula hospedeira , composição farmacêutica, método in vitro e uso de uma composição.
BR112014003704A2 (pt) moduladores ror gama
BR112014007675A2 (pt) tratamento de doença articular degenerativa
JP2016512205A5 (pt)
BR112012013888A2 (pt) preparados de combinação com antagonista de citocina e corticosteroide
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112021006167A8 (pt) Partículas de rna compreendendo polisarcosina
MX360304B (es) Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112016030730A8 (pt) composto
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]